Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Intra-erosive Power Doppler Signals Detected by Musculoskeletal Ultrasound with 1-year Radiographic Progression in Early Rheumatoid Arthritis.

The Journal of rheumatology·2026
Same author

Longitudinal observation of thrombotic events in patients with obstetric antiphospholipid syndrome.

Lupus·2026
Same author

Prevalence and prognostic value of activated protein C resistance and anti-protein C antibodies in patients with aPLs: an APS ACTION Registry study.

Rheumatology (Oxford, England)·2026
Same author

Consolidation Volume Assessed by Quantitative Computed Tomography Predicts the Prognosis of Pneumocystis Pneumonia in Rheumatic Diseases.

Modern rheumatology·2026
Same author

Hot topics in the antiphospholipid syndrome.

Current opinion in immunology·2026
Same author

Comprehensive Review of Antiphospholipid Syndrome: Over Four Decades of Advances and Challenges.

Cells·2026

Related Experiment Video

Updated: Jul 16, 2026

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Published on: October 7, 2009

Antiphospholipid antibodies: lessons from the bench.

Takao Koike1, Miyuki Bohgaki, Olga Amengual

  • 1Department of Medicine II, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan. tkoike@med.hokudai.ac.jp

Journal of Autoimmunity
|March 27, 2007
PubMed
Summary

Antiphospholipid antibodies (aPL) are linked to thrombosis and pregnancy issues in Antiphospholipid Syndrome (APS). Research shows aPL are associated with diverse conditions beyond blood clots, indicating multifactorial pathogenesis.

More Related Videos

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions
10:58

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions

Published on: July 27, 2017

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Experiment Videos

Last Updated: Jul 16, 2026

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Published on: October 7, 2009

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions
10:58

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions

Published on: July 27, 2017

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Immunology
  • Rheumatology
  • Hematology

Background:

  • Antiphospholipid antibodies (aPL) are immunoglobulins found in various autoimmune and infectious diseases.
  • Increased interest in anticardiolipin antibodies (aCL) since the 1980s due to their association with thrombosis.
  • Antiphospholipid Syndrome (APS) is defined by thrombosis and pregnancy morbidity linked to aPL, including lupus anticoagulant (LA).

Purpose of the Study:

  • To summarize the association of antiphospholipid antibodies (aPL) with thrombosis and other clinical manifestations.
  • To highlight the broadened spectrum of symptoms related to aPL presence.
  • To discuss proposed mechanisms underlying the thrombotic tendency in aPL-associated conditions.

Main Methods:

  • Review of literature on antiphospholipid antibodies (aPL).
  • Analysis of clinical associations and proposed pathogenetic mechanisms.
  • Synthesis of information regarding thrombosis and pregnancy morbidity in APS.

Main Results:

  • Thrombosis is the primary manifestation in patients with aPL.
  • A wide range of other conditions are associated with aPL, including thrombocytopenia, neurological and psychiatric syndromes, livedo reticularis, skin ulcers, hemolytic anemia, pulmonary hypertension, cardiac valve abnormalities, and atherosclerosis.
  • The pathogenesis of thrombosis in aPL-associated conditions is multifactorial.

Conclusions:

  • Antiphospholipid antibodies (aPL) are associated with a broad spectrum of clinical manifestations beyond thrombosis.
  • The pathogenesis of aPL-related disorders is complex and likely involves multiple factors.
  • Further research is needed to fully elucidate the mechanisms driving these diverse clinical outcomes.